MedTrace Logo

Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma

NCT03623854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-04-16

No results posted yet for this study

Summary

This phase II trial studies how well nivolumab and relatlimab work in treating participants with chordoma that has spread to other places in the body. Monoclonal antibodies, such as nivolumab and relatlimab, may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Chordoma
  • Locally Advanced Chordoma
  • Metastatic Chordoma
  • Unresectable Chordoma

Interventions

BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Relatlimab

Given via infusion

Sponsors & Collaborators

Principal Investigators

  • Arun Singh · UCLA / Jonsson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-03
Primary Completion
2023-09-28
Completion
2023-09-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03623854 on ClinicalTrials.gov